And...you haven't mentioned HTI-501 much or lately, which had positive-looking early results shared on June 29th for their current phase 1/2 cellulite study. I think it is wholly owned by halo and if I remember correctly from some article, the estimated market for cellulite alone dwarfs most or all of the other drugs halo is partnered with. That is not to even mention how HTI-501 could also help with other conditions such as aesthetic and connective tissue disorders like keloid and hypertrophic scarring, localized scleroderma, frozen shoulder syndrome and Dupuytren's contracture.
I bring this up since it seems to me HTI-501 is the often overlooked giant in terms of potential future revenues.
yes I think it will have revenues in excess of Botox ($2B) when approved- But that's a few years off- Next interim report next Spring at 10th annual cosmetic derm world meeting- the reason it will exceed Botox is that it's MUCH easier to inject- Botox is a poison- it travels and can cause a droopy eyelid or a Bells Palsy picture for Months if not done right- HTI-501 is shot into fat and doesn't travel- ph Neutralized quickly.
Roche Pharm made $4Billion on MabThera- the drug that the CEO of Halozyme will soon be ruled on by the European Medical council's adviosory committee, having already been passed by their safety committee- bet Jan and Oct 1 2013- OUTSIDE the US- So, Halo will make 5% of sales of its subcutaneous version- I am projecting just how much that migh add up to- be well and thanks for asking